The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1184
June 7, 2004
View Complete Issue         Table of Contents 2019 
Two New Drugs for Colon Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Two New Drugs for Colon Cancer
June 7, 2004 (Issue: 1184)
Cetuximab (Erbitux - ImClone Systems/Bristol-Myers Squibb), an epidermal growth factor receptor (EGFR) inhibitor, and bevacizumab (Avastin - Genentech), the first vascular endothelial growth factor angiogenesis inhibitor, have recently been approved...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Two New Drugs for Colon Cancer
Article code: 1184b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.